Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maya H Buch

Showing results (81-90 of 180) with videos related to

Pageof 18
Sort By:
The British Journal of Radiology|May 2, 2020
Feasibility of MRI based extracellular volume fraction and partition coefficient measurements in thigh muscleAlex F Goodall, David A Broadbent, Raluca B Dumitru, et al.
Rheumatology (Oxford, England)|January 29, 2025
Foot peripheral sensory neuropathy: a frequent disabling manifestation in systemic sclerosisBegonya Alcacer-Pitarch, Marco Di Battista, Anthony C Redmond, et al.
RMD Open|April 12, 2024
Understanding the psychosocial determinants of effective disease management in rheumatoid arthritis to prevent persistently active disease: a qualitative studyNkasi Stoll, Mrinalini Dey, Sam Norton, et al.
Arthritis Research & Therapy|May 30, 2019
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA studyJanusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, et al.
Annals of the Rheumatic Diseases|July 8, 2018
Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid ArthritisLianne Kearsley-Fleet, Rebecca Davies, Diederik De Cock, et al.
Annals of the Rheumatic Diseases|January 4, 2014
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapySudipto Das, Edward M Vital, Sarah Horton, et al.
Heart (British Cardiac Society)|January 18, 2024
Use of coronarycomputed tomography for cardiovascular risk assessment in immune-mediated inflammatory diseasesMarta Peverelli, Robert T Maughan, Deepa Gopalan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 9, 2022
No differences in myocardial perfusion between treatment-naive, early rheumatoid arthritis patients and healthy controlsJohn D Biglands, Bara Erhayiem, Graham Fent, et al.
Rheumatology (Oxford, England)|January 12, 2021
Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritisAndrew R Melville, Md Yuzaiful Md Yusof, John Fitton, et al.
Nature Reviews. Rheumatology|February 1, 2024
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinicianZoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, et al.
Pageof 18

Showing results (81-90 of 180) with videos related to

Sort By:
Pageof 18
The British Journal of Radiology|May 2, 2020
Feasibility of MRI based extracellular volume fraction and partition coefficient measurements in thigh muscleAlex F Goodall, David A Broadbent, Raluca B Dumitru, et al.
Rheumatology (Oxford, England)|January 29, 2025
Foot peripheral sensory neuropathy: a frequent disabling manifestation in systemic sclerosisBegonya Alcacer-Pitarch, Marco Di Battista, Anthony C Redmond, et al.
RMD Open|April 12, 2024
Understanding the psychosocial determinants of effective disease management in rheumatoid arthritis to prevent persistently active disease: a qualitative studyNkasi Stoll, Mrinalini Dey, Sam Norton, et al.
Arthritis Research & Therapy|May 30, 2019
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA studyJanusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, et al.
Annals of the Rheumatic Diseases|July 8, 2018
Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid ArthritisLianne Kearsley-Fleet, Rebecca Davies, Diederik De Cock, et al.
Annals of the Rheumatic Diseases|January 4, 2014
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapySudipto Das, Edward M Vital, Sarah Horton, et al.
Heart (British Cardiac Society)|January 18, 2024
Use of coronarycomputed tomography for cardiovascular risk assessment in immune-mediated inflammatory diseasesMarta Peverelli, Robert T Maughan, Deepa Gopalan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 9, 2022
No differences in myocardial perfusion between treatment-naive, early rheumatoid arthritis patients and healthy controlsJohn D Biglands, Bara Erhayiem, Graham Fent, et al.
Rheumatology (Oxford, England)|January 12, 2021
Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritisAndrew R Melville, Md Yuzaiful Md Yusof, John Fitton, et al.
Nature Reviews. Rheumatology|February 1, 2024
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinicianZoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, et al.
Pageof 18